Oegstgeest
Zuid-Holland
ISA
is a Netherlands-based biopharmaceutical company that develops and commercializes cellular immunotherapies for the treatment of cancer and SARS diseases... Read moreISA
is a Netherlands-based biopharmaceutical company that develops and commercializes cellular immunotherapies for the treatment of cancer and SARS diseases... Read moreNews
Dec 12, 2023
StreetInsider
Press Release: ISA : ISA Pharmaceuticals reports highlights of randomized Phase 2 cancer vaccine trial in head & neck cancer
Oct 27, 2023
Pharamceutical Technology
ISA: Peltopepimut-s by ISA Pharmaceuticals for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approval
Sep 01, 2023
Pharmabiz
ISA: ISA Pharma announces first patient dosed in HEBPEP study of ISA104 with chronic hepatitis B
Jun 06, 2023
StreetInsider
Press Release: ISA : The combination of ISA101b and Libtayo shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy
May 25, 2023
StreetInsider
Press Release: ISA : ISA Pharmaceuticals to Present First Clinical Trial Data from the Phase II Study of ISA101b and Libtayo (cemiplimab) Combination in Head and Neck Cancer at the ASCO Annual Meeting 2023
Apr 27, 2023
FinanzNachrichten
ISA: ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting
Apr 20, 2023
Yahoo
ISA: ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences in May and June of 2023
Jan 04, 2023
FinanzNachrichten
ISA: ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma
Dec 01, 2022
Clinical Trials Arena
ISA: ISA concludes subject enrolment in HPV16 positive OPC therapy trial
Nov 08, 2022
FinanzNachrichten
ISA: ISA Pharmaceuticals: First-in-Human Study: Amplivant Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy
ISA Competitors
1
2
3
4
5